Outlook Therapeutics, Inc.
OTLK
$2.91
$0.238.58%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.51M | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.51M | -- | -- | -- | -- |
| Cost of Revenue | 531.50K | -- | 9.66M | 12.52M | 147.40K |
| Gross Profit | 973.90K | -- | -9.66M | -12.52M | -147.40K |
| SG&A Expenses | 9.68M | 7.98M | 11.95M | 10.35M | 8.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.25M | 12.39M | 21.61M | 22.88M | 19.56M |
| Operating Income | -15.75M | -12.39M | -21.61M | -22.88M | -19.56M |
| Income Before Tax | -20.15M | -46.35M | 17.38M | 5.69M | 44.41M |
| Income Tax Expenses | -- | 2.80K | -- | 0.00 | -- |
| Earnings from Continuing Operations | -20.15M | -46.36M | 17.38M | 5.69M | 44.41M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.15M | -46.36M | 17.38M | 5.69M | 44.41M |
| EBIT | -15.75M | -12.39M | -21.61M | -22.88M | -19.56M |
| EBITDA | -15.72M | -12.36M | -21.58M | -22.85M | -19.53M |
| EPS Basic | -0.55 | -1.50 | 0.72 | 0.24 | 1.91 |
| Normalized Basic EPS | -0.30 | -0.94 | 0.48 | 0.16 | 0.99 |
| EPS Diluted | -0.55 | -1.50 | 0.72 | 0.24 | -0.89 |
| Normalized Diluted EPS | -0.30 | -0.94 | 0.48 | 0.16 | 0.90 |
| Average Basic Shares Outstanding | 36.96M | 30.87M | 24.23M | 23.73M | 23.23M |
| Average Diluted Shares Outstanding | 36.96M | 30.87M | 24.23M | 23.73M | 25.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |